Charles Schwab Investment Management Inc Aadi Bioscience, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	SELL	$1.59 - $2.44 $13,187 - $20,237	-8,294 Reduced 18.28%	37,075 $86,000
Q2 2023 Aug 09, 2023	BUY	$6.84 - $8.56 $28,386 - $35,524	4,150 Added 10.07%	45,369 $310,000
Q4 2022 Feb 13, 2023	BUY	$11.99 - $14.5 $59,542 - $72,007	4,966 Added 13.7%	41,219 $528,000
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $43,271 - $51,149	-3,597 Reduced 9.03%	36,253 $513,000
Q2 2022 Aug 15, 2022	BUY	$11.57 - $17.92 $461,064 - $714,112	39,850 New	39,850 $491,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $63.1M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.